Episode 76
Biotech Hangout
Disappointing Results of F4 Cirrhosis Nash Study and Impact on Stock
The chapter discusses the disappointing results of a study on F4 cirrhosis Nash and the potential negative impact on the stock. They mention concerns about the timeline for a larger phase 3 study and the fear surrounding the F2-3 space.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
